COL11A1 promotes Sorafenib resistance in lung adenocarcinoma: from bioinformatic discovery to functional validation.
4 affiliations
- 1Department of Cardiology, Guiqian International General Hospital, Guiyang, Guizhou, 550000, China. [email protected].
- 2Department of Respiratory, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, Guizhou, 550000, China. [email protected].
- 3Department of Respiratory, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, Guizhou, 550000, China. [email protected].
- 4Department of Respiratory, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, Guizhou, 550000, China. [email protected].
Abstract
Objective
To investigate the expression characteristics, prognostic value, and role of COL11A1 in Sorafenib resistance in lung adenocarcinoma (LUAD).Methods
The expression differences of COL11A1 in LUAD were analyzed based on The Cancer Genome Atlas (TCGA) database. Kaplan-Meier survival analysis was performed to evaluate prognostic value, and drug sensitivity analysis, molecular docking analysis and molecular dynamics simulation were conducted. Molecular mechanisms were explored using Weighted Gene Co-expression Network Analysis (WGCNA) and functional enrichment analysis. A549/Sorafenib-resistant and H1299/Sorafenib-resistant cell line was established, and the effects of COL11A1 knockdown and overexpression on cell proliferation, apoptosis, migration, and invasion were examined. Western blot was performed to assess the protein expression levels of p-Akt, E-cadherin, and Vimentin to explore the underlying molecular mechanisms.Results
COL11A1 was significantly upregulated in LUAD, and patients with high expression showed poor prognosis. Drug sensitivity analysis, molecular docking analysis and molecular dynamics simulation revealed that COL11A1 was associated with Sorafenib. Functional analysis indicated that COL11A1 primarily participated in extracellular matrix remodeling and collagen metabolic processes. Cell experiments confirmed that COL11A1 was highly expressed in resistant cells. Mechanistically, COL11A1 was found to activate the Akt signaling pathway and promote epithelial-mesenchymal transition (EMT) in Sorafenib-resistant LUAD cells, as evidenced by elevated p-Akt and Vimentin levels alongside reduced E-cadherin expression.Conclusion
COL11A1 mediates Sorafenib resistance by inhibiting tumor cell apoptosis, activating the Akt signaling pathway, and promoting EMT, and can serve as a potential prognostic biomarker and therapeutic target for overcoming drug resistance in LUAD.
Related
- Unraveling the role of MCM7 in cancer: a comprehensive analysis and functional validation from pan-cancer to lung adenocarcinoma
- Huoxi Qufeng medicinal liquor alleviates rheumatoid arthritis lesions: Bioinformatic prediction of EGFR-related JAK-STAT/PI3K-Akt pathways and in vivo pharmacological validation
- Metabolic signature of phosphoethanolamine and arginine pathways predicts prognosis and immunotherapy resistance in lung adenocarcinoma
- Pretreatment prediction of early severe treatment-related toxicity in older patients with lung adenocarcinoma: same-center temporal validation of a risk model
- A novel three-CpG signature for lung adenocarcinoma diagnosis: integrating multi-omics, machine learning, and clinical validation
BibTeX
@article{yang2026col11a1,
title = {{COL11A1 promotes Sorafenib resistance in lung adenocarcinoma: from bioinformatic discovery to functional validation.}},
author = {Shiyu Yang and Xia Lin and Wen Liu and Xiwei Hu},
journal = {BMC medical genomics},
year = {2026},
month = aug,
doi = {10.1186/s12920-026-02446-y},
url = {https://europepmc.org/article/MED/42972426},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - COL11A1 promotes Sorafenib resistance in lung adenocarcinoma: from bioinformatic discovery to functional validation.
AU - Shiyu Yang
AU - Xia Lin
AU - Wen Liu
AU - Xiwei Hu
PY - 2026
DA - 2026/08/05
JO - BMC medical genomics
DO - 10.1186/s12920-026-02446-y
UR - https://europepmc.org/article/MED/42972426
AB - Objective To investigate the expression characteristics, prognostic value, and role of COL11A1 in Sorafenib resistance in lung adenocarcinoma (LUAD).Methods The expression differences of COL11A1 in LUAD were analyzed based on The Cancer Genome Atlas (TCGA) database. Kaplan-Meier survival analysis was performed to evaluate prognostic value, and drug sensitivity analysis, molecular docking analysis and molecular dynamics simulation were conducted. Molecular mechanisms were explored using Weighted Gene Co-expression Network Analysis (WGCNA) and functional enrichment analysis. A549/Sorafenib-resistant and H1299/Sorafenib-resistant cell line was established, and the effects of COL11A1 knockdown and overexpression on cell proliferation, apoptosis, migration, and invasion were examined. Western blot was performed to assess the protein expression levels of p-Akt, E-cadherin, and Vimentin to explore the underlying molecular mechanisms.Results COL11A1 was significantly upregulated in LUAD, and patients with high expression showed poor prognosis. Drug sensitivity analysis, molecular docking analysis and molecular dynamics simulation revealed that COL11A1 was associated with Sorafenib. Functional analysis indicated that COL11A1 primarily participated in extracellular matrix remodeling and collagen metabolic processes. Cell experiments confirmed that COL11A1 was highly expressed in resistant cells. Mechanistically, COL11A1 was found to activate the Akt signaling pathway and promote epithelial-mesenchymal transition (EMT) in Sorafenib-resistant LUAD cells, as evidenced by elevated p-Akt and Vimentin levels alongside reduced E-cadherin expression.Conclusion COL11A1 mediates Sorafenib resistance by inhibiting tumor cell apoptosis, activating the Akt signaling pathway, and promoting EMT, and can serve as a potential prognostic biomarker and therapeutic target for overcoming drug resistance in LUAD.
SN - 1755-8794
ER -